KMT2A and leukemia: A therapeutic potential and antileukemic activity was recently demonstrated in a study of the MM-401 compound targeting MLL1/KMT2A H3K4 methyltransferase activity in mixed lineage leukemia, suggesting that wild type MLL1 is necessary for MLL1-rearrangement driven leukemia [90].